Baxter Receives Warning Letter For Fibrin Sealant Promotional Materials
This article was originally published in The Gray Sheet
Executive Summary
An FDA warning letter charges that promotional materials for Baxter's Tisseel fibrin sealant constitute misbranding of the product
You may also be interested in...
FDA To Review Baxter's Promotional Practices After Most Recent Warning Letter
A physician brochure for alpha 1-proteinase inhibitor Aralast NP prompts FDA to ask the firm to overhaul its approach to promotion and explain why "you expect these new policies and procedures to succeed."
Baxter Alerted FDA To Problem Before Receiving Warning Letter, Firm Says
Baxter says it has already corrected a key problem cited in an FDA warning letter released Oct. 20, and that it was the company itself that first identified and voluntarily reported the issue to FDA
Baxter Alerted FDA To Problem Before Receiving Warning Letter, Firm Says
Baxter says it has already corrected a key problem cited in an FDA warning letter released Oct. 20, and that it was the company itself that first identified and voluntarily reported the issue to FDA